Provider of label-free drug discovery solutions, SAMDI Tech, has announced it has received a small business innovation research (SBIR) grant from the National Institutes of Health (NIH) to develop the first cell-based and label-free, high throughput assay of specific enzyme activities.
Grant
“This award will enable us to expand SAMDI Tech’s leadership in label-free, high-throughput drug discovery solutions,” said Dr Zack Gurard-Levin, chief scientific officer at SAMDI Techand principal investigator on the grant. “Additionally, developing a new cell-based assay for specific enzyme activities will allow us to contribute to the advancement of healthcare and drug discovery research.”
The funding is provided by the National Center for Advancing Translational Sciences (NCATS) of the NIH for Phase I of the project.
In order to receive funding, NIH award winners are required to complete a competitive application and review process and SBIR grants are awarded to companies that demonstrate scientific excellence and technological innovation in their project proposals.